Displaying 11–20 of 254 research results
Jun 12, 2023
An emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
Jun 1, 2023
The company is expanding the trial to enroll younger patients with less advanced disease
May 23, 2023
The Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
May 2, 2023
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
May 1, 2023
During his Proctor Award Lecture, Dr. Pierce reviewed encouraging clinical trial results for Editas’ CRISPR/Cas9 treatment for people with LCA10
Apr 28, 2023
Dr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
Apr 21, 2023
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
Mar 30, 2023
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
Feb 18, 2023
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
Jan 3, 2023
The company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023